Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$38.57M, compared with -$16.55M a year earlier. Trailing-twelve-month EBITDA was -$158.55M.

Context

  • EBITDA amounted to 4881.5% of revenue in FY2025, up 4686.2 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of -$50.51M (+63.0%) for the fiscal year ending Dec 2026, a step up from the -79.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$38.57M+61.9% QoQ
Last fiscal yearDec 2025
-$136.54M-79.7% YoY
LTMMar 2026
-$158.55M-341.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-133.0%-251.6%-118.6 pp
1 year-79.7%+63.0%+142.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(136.54M) USD
Year-over-year change
-79.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -341.7% is the lowest of 9, against a peer median of +15.9%.
  • EBITDA amounts to 8932.3% of revenue for RNAC, versus a peer median of 161.1%.
RNAC Competitors
EBITDA for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-$6.67M USD+35.5%—13.1%
MDWDMediWound Ltd.LTM Mar 2026-$14.84M USD+39.0%—102.5%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026-$35.22M USD———
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$45.49M USD-75.7%——
NAUTNautilus Biotechnology, Inc.LTM Mar 2026-$50.77M USD+11.7%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$52.72M USD+20.1%—161.1%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026-$69.83M USD-147.0%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.35M USD-214.9%—142957.6%
IVAInventiva S.A.FY2025-€128.15M EUR+23.0%—2858.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$158.55M USD-341.7%—8932.3%
Peer median (excluding RNAC) —+15.9%—161.1%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.08M110.78M26M38.91M2.8M
Cost of Revenue02.04M000
Gross Profit85.08M108.74M26M38.91M2.8M
Gross Margin100.0%98.2%100.0%100.0%100.0%
Research & Development68.74M72.38M71.26M45.11M58.03M
Selling, General & Admin20.94M23.86M40.45M30.13M31.47M
Operating Expenses89.67M94.2M112.42M82.81M89.5M
Depreciation & Amortization1.72M2.04M843K1.15M2.96M
EBITDA(5.16M)39.84M(235.03M)(75.99M)(136.54M)
EBITDA Margin-6.1%36.0%-903.8%-195.3%-4881.5%
Operating Income(4.6M)14.54M(86.42M)(43.9M)(86.71M)
Operating Margin-5.4%13.1%-332.3%-112.8%-3099.9%
Interest Income004.96M7.39M6.58M
Interest Expense2.84M3.03M2.83M00
Other Income / Expenses(5.12M)20.23M(152.29M)(33.24M)(52.79M)
Income Before Tax(9.72M)34.77M(238.71M)(77.14M)(139.5M)
Pre-Tax Margin-11.4%31.4%-918.0%-198.2%-4987.3%
Income Tax Expense15.97M(609K)(19M)287K(9.19M)
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Net Margin-30.2%31.9%-844.9%-199.0%-4658.6%
EPS (Basic)(6.74)7.33(49.76)(2.99)(5.02)
EPS (Diluted)(6.60)3.00(49.76)(3.29)(5.02)
Weighted Avg Shares3.18M4.02M5.17M25.91M25.97M
Weighted Avg Shares (Diluted)3.18M4.05M5.17M23.69M25.97M

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.